1 Min Read
Dec 22 (Reuters) - Sun Pharmaceutical Industries Ltd
* Says Sun Pharma to acquire branded oncology product Odomzo for global markets
* Says acquisition of Odomzo from Novartis
* Says greement has been signed for an upfront payment of US$ 175 million and additional milestone payments.
* says Odomzo is used for treatment of adult patients with labcc that has recurred following surgery or radiation therapy Source text: bit.ly/2i2LK7M Further company coverage: